Antimicrobial Therapy in Immunocompromised and Critically Ill Patients: Management and Perspectives Palazzo dei Congressi - LUGANO 29-30 May 2014 BACKGROUND The incidence and diagnosis of viral, bacterial and fungal infections in the critically ill and immunocompromised patients has dramatically increased and the number of new, immunocompromising therapies is also rapidly growing. New drugs for the treatment of invasive fungal infections have joined the existing therapeutic armamentarium, yet the mortality caused by Candida spp., mould infections is still unacceptably high. Known and emerging viral infections are also attracting the interest of most specialists and, despite the introduction of new diagnostic tools, they are still causing serious problems in the ICU and complicate the daily management of immunocompromised patients. Finally, the increasing number of infections caused by multidrug resistant bacteria jeopardizes the success of therapeutic interventions. Treatment of infections in the critically ill and in the classical immunocompromised patient is fraught with a number of open questions. The symposium aims at updating these issues and providing a discussion forum for clinicians and microbiologists actively involved in the treatment of ICU and immunocompromised patients, including haemato-oncologic diseases, solid organ and bone marrow transplantation and autoimmune diseases. OBJECTIVES The symposium will discuss common issues and controversies related to the diagnosis and treatment of infections in critically ill and immunocompromised patients, to provide real-life experience that can easily translate into daily clinical practice. SCIENTIFIC COMMITTEE: Enos Bernasconi, MD Christian Garzoni, MD Paolo Grossi, MD Oscar Marchetti, MD Orlando Petrini, PhD Francesco Scaglione, MD
PRELIMINARY PROGRAM 29 MAY - THURSDAY 10:00-10:15 Welcome, Introduction Enos Bernasconi SESSION I: Challenges in prevention and treatment of fungal infections 10:15-10:45 Antibacterial and antifungal stewardship - the clinical significance of laboratory results Robert Masterton 10:45-11:15 Azole-resistant Aspergillus species in the clinical settings where do they come from? Paul Verweij 11:15-11:30 Coffee Break 11:30-11:50 Antifungal prophylaxis in high-risk patients? Yes Tony Pagliuca 11:50-12:10 Antifungal prophylaxis in high-risk patients? No Christian Van Delden 12:10-12:30 Q&A Discussion 12:30-13:45 Lunch
SESSION II: Therapeutic challenges in the era of antibiotic resistance 13:45-14:15 VAP treatment: when and how Paolo Grossi 14:15-14:45 Intra-abdominal infections: antimicrobials and surgery Gabriele Sganga 14:45-15:15 Treatment of complicated skin and skin-structure infections Christian Eckmann 15:15-15:45 Q&A Discussion 15:45-16:15 Coffee Break SESSION III: Candida infections in the ICU 16:15-16:45 What is new in Candida epidemiology Philippe Montravers 16:45-17:15 Antifungal approaches: Any news from biomarkers? Oscar Marchetti 17:15-17:45 Treatment options and guidelines Philippe Eggimann 17:45-18:00 Q&A Discussion
30 MAY - FRIDAY SESSION IV: Viral infections emerging threats and treatments 08:00-08:30 Respiratory viruses (Influenza? Others?) Paolo Grossi 08:30-09:00 Immunogenetics of viral infections Pierre Yves Bochoud 09:00-09:15 Q&A Discussion SESSION V: Viral infections in transplant patients 09:15-10:15 CMV infections in transplant patients pros and cons of prophylaxis Pascal Meylan, Hans Hirsch 10:15-10:45 Coffee Break 10:45-11:15 Infection disease burden in transplant recipients: The Swiss Transplant Cohort Study Nikolas Müller 11:15-11:45 New drugs for Hepatitis C in the transplant patient Patrizia Burra 11:45-12:15 Meeting the challenge of HIV, HCV in transplantation: a pharmacologic nightmare Beat Müllhaupt 12:15-12:45 Q&A Discussion 12:45-14:00 Lunch break
SESSION VI: Interactive cases 14:00-16:00 Presentation of cases